Serum Cholesterol Level Changes during Gonadotropin-Releasing Hormone-Agonist Therapy in Premenopausal Female Patients with Breast Cancer
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: To investigate the changes in cholesterol levels during medical ovarian suppression. Methods: We reviewed the medical records and blood test results of 187 female patients with breast cancer who underwent gonadotropin-releasing hormone (GnRH)-agonist therapy for > 24 weeks at our hospital between 1 January 2018 and 31 December 2020. The study excluded patients in this cohort who had previously been diagnosed with dyslipidemia, diabetes, or had recently received lipid-lowering agents, resulting in a final sample size of 152 participants. The age at diagnosis and preoperative body mass index (BMI) were included as baseline demographics. A generalized additive mixed model was applied to analyze the relationship between the duration of GnRH-agonist treatment and changes in cholesterol levels. Results: The study participants had a mean age of 42.5 ± 5.2 years and a mean preoperative BMI of 23.0 ± 3.6 kg/m2; the mean GnRHagonist therapy duration was 19.3 months (range: 5.6–37.7 months); and the total cholesterol level before GnRH-agonist treatment was 171 mg/dL that was significantly higher at 181 mg/dL (P = 0.03) during the most recent measurement. The total cholesterol level was unaffected by the GnRH-agonist therapy until 19.3 months after which it significantly increased by 1.28 mg/dL per month (P = 0.011). There was no significant effect of age, preoperative BMI, or the glomerular filtration rate on the total cholesterol levels. Conclusions: Long-term GnRH agonist therapy for > 19 months can cause a significant increase in the serum cholesterol levels. To prevent complications, patients receiving the treatment should be informed and monitored for the possible progression of dyslipidemia.
Abstract
Objectives: To investigate the changes in cholesterol levels during medical ovarian suppression. Methods: We reviewed the medical records and blood test results of 187 female patients with breast cancer who underwent gonadotropin-releasing hormone (GnRH)-agonist therapy for > 24 weeks at our hospital between 1 January 2018 and 31 December 2020. The study excluded patients in this cohort who had previously been diagnosed with dyslipidemia, diabetes, or had recently received lipid-lowering agents, resulting in a final sample size of 152 participants. The age at diagnosis and preoperative body mass index (BMI) were included as baseline demographics. A generalized additive mixed model was applied to analyze the relationship between the duration of GnRH-agonist treatment and changes in cholesterol levels. Results: The study participants had a mean age of 42.5 ± 5.2 years and a mean preoperative BMI of 23.0 ± 3.6 kg/m2; the mean GnRHagonist therapy duration was 19.3 months (range: 5.6–37.7 months); and the total cholesterol level before GnRH-agonist treatment was 171 mg/dL that was significantly higher at 181 mg/dL (P = 0.03) during the most recent measurement. The total cholesterol level was unaffected by the GnRH-agonist therapy until 19.3 months after which it significantly increased by 1.28 mg/dL per month (P = 0.011). There was no significant effect of age, preoperative BMI, or the glomerular filtration rate on the total cholesterol levels. Conclusions: Long-term GnRH agonist therapy for > 19 months can cause a significant increase in the serum cholesterol levels. To prevent complications, patients receiving the treatment should be informed and monitored for the possible progression of dyslipidemia.
참고문헌 (26)
- Yao H, "Triple-negative breast cancer : is there a treatment on the horizon?", Oncotarget, 8, pp.1913~1924 (2017)
- Early Breast Cancer Trialists᾽ Collaborative Group(EBCTCG), "Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival : an overview of the randomised trials", Lancet, 365, pp.1687~1717 (2005)
- Schmid P, "Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer : the TABLE study", J Clin Oncol, 25, pp.2509~2515 (2007)
- Pagani O, "Adjuvant exemestane with ovarian suppression in premenopausal breast cancer", N Engl J Med, 371, pp.107~118 (2014)
- Francis PA, "Tailoring adjuvant endocrine therapy for premenopausal breast cancer", N Engl J Med, 379, pp.122~137 (2018)
- Rocca WA, "Bilateral oophorectomy and accelerated aging : cause or effect?", J Gerontol A Biol Sci Med Sci, 72, pp.1213~1217 (2017)
- Wang K, "Comparison of changes in lipid profiles of premenopausal women with early-stage breast cancer treated with different endocrine therapies", Sci Rep, 12, pp.22650~ (2022)
- Kang YK, "The effects of endocrine therapies on lipid profiles in Chinese young women with early breast cancer", Front Oncol, 11, pp.759595~ (2021)
- Walsh EM, "Management of hormone receptor-positive, HER2-negative early breast cancer", Semin Oncol, 47, pp.187~200 (2020)
- Crew KD, "Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer", J Clin Oncol, 25, pp.3877~3883 (2007)
- Matthews A, "Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors : systematic review", BMJ, 363, pp.k3845~ (2018)
- Podfigurna-Stopa A, "Premature ovarian insufficiency : the context of long-term effects", J Endocrinol Invest, 39, pp.983~990 (2016)
- Garg R, "Association of atherosclerosis with dyslipidemia and co-morbid conditions : a descriptive study", J Nat Sci Biol Med, 6, pp.163~168 (2015)
- Phan BAP, "Dyslipidemia in women : etiology and management", Int J Womens Health, 6, pp.185~194 (2014)
- Kim KI, "Dyslipidemia in older adults and management of dyslipidemia in older patients", J Lipid Atheroscler, 4, pp.1~6 (2015)
- Weingärtner O, "Relationship between cholesterol synthesis and intestinal absorption is associated with cardiovascular risk", Atherosclerosis, 210, pp.362~365 (2010)
- Verschuren WM, "Serum total cholesterol and longterm coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study", JAMA, 274, pp.131~136 (1995)
- Ipsen DH, "Dyslipidemia : obese or not obese-that is not the question", Curr Obes Rep, 5, pp.405~412 (2016)
- Kannel WB, "Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study", Ann Intern Med, 74, pp.1~12 (1971)
- Jensen JT, "Ovarian lipid metabolism modulates circulating lipids in premenopausal women", J Clin Endocrinol Metab, 102, pp.3138~3145 (2017)
- Knauff EA, "Lipid profile of women with premature ovarian failure", Menopause, 15, pp.919~923 (2008)
- Chu MC, "Elevated basal FSH in normal cycling women is associated with unfavourable lipid levels and increased cardiovascular risk", Hum Reprod, 18, pp.1570~1573 (2003)
- Torosyan N, "Dyslipidemia in midlife women : approach and considerations during the menopausal transition", Maturitas, 166, pp.14~20 (2022)
- Matthews KA, "Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition?", J Am Coll Cardiol, 54, pp.2366~2373 (2009)
- Caleffi M, "Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain", J Endocrinol, 119, pp.335~339 (1988)
- Ntukidem NI, "Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen", Clin Pharmacol Ther, 83, pp.702~710 (2008)